Adjuvant concurrent chemoradiotherapy for early-stage cervical cancer patients with intermediate-risk factors in the era of intensity-modulated radiation therapy
Journal of Gynecologic Oncology · 2026
DOI: 10.3802/jgo.2026.37.e93 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Sitong Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Radiotherapy, Intensity-Modulated, Chemoradiotherapy, Adjuvant. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: To investigate whether adjuvant concurrent chemotherapy with pelvic intensity-modulated radiotherapy (IMRT) improves the outcome of patients with early-stage cervical cancer with intermediate risk factors (IRFs) compared with IMRT alone. METHODS: This study included a cohort of 244 women from January 2012 to October 2023 who underwent radical hysterectomy along with pelvic lymph node dissection (PLND) for stage IB-IIA cervical cancer with IRFs. One hundred thirty-nine patients were postoperatively treated with pelvic IMRT (45.0-50.4 Gy) and adjuvant concurrent chemoradiotherapy (CCRT) (weekly cisplatin or weekly or triweekly combination of paclitaxel and cisplatin). One hundred five patients were treated with pelvic IMRT alone. The significance of clinical parameters, overall survival (OS), and recurrence-free survival (RFS) of each arm were analyzed. RESULTS: The median follow-up period was 61.2 months, with a range spanning from 6.3 to 144.4 months. The 5-year OS rates in the patients in the radiotherapy (RT) and CCRT arms were 96.7% and 94.4%, respectively (p=0.271). Five-year RFS was 88.1% in the RT arm and 86.9% in the CCRT arm (p=0.740). Multivariate analysis identified adenocarcinoma (AC) histology as the only significant prognostic factor affecting OS and RFS. CONCLUSION: This study demonstrates that even in the era of IMRT, CCRT is not more effective than RT alone in patients with stage IB-IIA cervical cancer with IRFs following radical hysterectomy with PLND.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Gynecological Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. lin.genlai@zs-hospital.sh.cn.
ORCID-Profile: Sitong Wang, Gui-Fen Ma, Chunli Xiao, Juan Liu, Tingyan Shi, Li Ma, Gen-Lai Lin
Zitieren
APA
Wang, S., Ma, G. F., Xiao, C., Liu, J., Shi, T., Ma, L., & Lin, G. L. (2026). Adjuvant concurrent chemoradiotherapy for early-stage cervical cancer patients with intermediate-risk factors in the era of intensity-modulated radiation therapy. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e93
Vancouver
Wang S, Ma GF, Xiao C, Liu J, Shi T, Ma L, et al. Adjuvant concurrent chemoradiotherapy for early-stage cervical cancer patients with intermediate-risk factors in the era of intensity-modulated radiation therapy. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e93
BibTeX
@article{Wang2026,
author = {Wang, Sitong and Ma, Gui-Fen and Xiao, Chunli and Liu, Juan and Shi, Tingyan and Ma, Li and Lin, Gen-Lai},
title = {Adjuvant concurrent chemoradiotherapy for early-stage cervical cancer patients with intermediate-risk factors in the era of intensity-modulated radiation therapy},
journal = {Journal of Gynecologic Oncology},
year = {2026},
doi = {10.3802/jgo.2026.37.e93}
}
EUVIMED